Exploring the Theoretical Potential of Benzphetamine in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Level 5 - mechanism / opinion, no new human data
Mechanism-based theoretical review and editorial with no empirical clinical data.
PubMed 41476437 · doi:10.7759/cureus.100363
What was done
This editorial presented a theoretical pharmacological rationale evaluating whether benzphetamine HCl—a Schedule III amphetamine prodrug FDA-approved for obesity—could theoretically serve as an alternative treatment option amidst nationwide shortages of standard ADHD stimulants. The authors reviewed existing mechanism-of-action data regarding its metabolism into dextroamphetamine and dextromethamphetamine without conducting empirical clinical testing.
What was found
The abstract reports no quantitative experimental or clinical data. Prior literature noted that dextroamphetamine is more potent than parent benzphetamine and that their behavioral profiles differ. The authors concluded that the complete absence of clinical data in individuals with ADHD precludes any therapeutic or efficacy claims.
Why it matters
Persistent shortages of first-line stimulant medications have driven interest in alternative compounds that metabolize into active stimulants. This review highlights the mechanistic plausibility of benzphetamine while clarifying that clinical evidence is currently non-existent.
Limits
The paper is an editorial without new clinical or laboratory data. There are no clinical trials, pharmacokinetic studies in ADHD populations, safety evaluations, or direct comparative efficacy data for benzphetamine in treating ADHD.
Cited by
- supports Desoxyn is a prescription form of methamphetamine used to treat conditions like ADHD.